Trials / Conditions / Metastatic Gastric Carcinoma

Metastatic Gastric Carcinoma

15 registered clinical trials studyying Metastatic Gastric Carcinoma — 10 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Node-Sparing Short-Course Radiotherapy Plus First-Line Therapy and PD-1 Inhibitor in Unresectable/Metastastic NCT06980389	Sixth Affiliated Hospital, Sun Yat-sen University	Phase 2
Recruiting	Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in P NCT06364410	National Cancer Institute (NCI)	Phase 1
Recruiting	A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors NCT06586957	NiKang Therapeutics, Inc.	Phase 1
Terminated	A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors NCT06264921	NiKang Therapeutics, Inc.	Phase 1
Recruiting	A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People Wit NCT06251973	Memorial Sloan Kettering Cancer Center	Phase 2
Recruiting	Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasi NCT05802056	Mayo Clinic	Phase 1
Active Not Recruiting	Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or NCT04535401	National Cancer Institute (NCI)	Phase 1
Recruiting	Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tu NCT04704661	National Cancer Institute (NCI)	Phase 1
Active Not Recruiting	Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events NCT05038254	M.D. Anderson Cancer Center	N/A
Recruiting	Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations NCT04550494	National Cancer Institute (NCI)	Phase 2
Recruiting	PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorecta NCT04329494	City of Hope Medical Center	Phase 1
Recruiting	Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers NCT04221893	University of California, San Francisco	N/A
Terminated	CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors NCT02757391	M.D. Anderson Cancer Center	Phase 1
Recruiting	Intravital Microscopy in Human Solid Tumors NCT03823144	Mayo Clinic	N/A
Completed	Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal NCT03008278	National Cancer Institute (NCI)	Phase 1 / Phase 2